Storia della carriera di Po-Shun Lee
Precedenti posizioni note di Po-Shun Lee
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| PROTEOSTASIS THERAPEUTICS, INC. | Direttore Tecnico/Scientifico/R&S | 01/11/2014 | 22/07/2019 |
| VERTEX PHARMACEUTICALS INCORPORATED | Corporate Officer/Principal | 01/08/2010 | 01/01/2013 |
Critical Biologics Corp.
 Critical Biologics Corp. Medical SpecialtiesHealth Technology Critical Biologics Corp. develops and commercializes diagnostics and therapeutics drugs. The firm focuses in the development of a theranostic platform to screen and treat both acute and chronic patients with low plasma gelsolin levels (hypogelsolinemia) at high risk of life-threatening complications. The company was founded by James W. Fordyce, Terence S. Russell, Shun Lee Po, and Thomas P. Stossel in 2006 and is headquartered in Cambridge, MA. | Fondatore | 18/12/2009 | - |
Formazione di Po-Shun Lee
| The Johns Hopkins University | Undergraduate Degree |
| University of Pennsylvania | Doctorate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 6 |
Posizioni
| Founder | 1 |
| Undergraduate Degree | 1 |
| Doctorate Degree | 1 |
Settori
| Health Technology | 4 |
| Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| VERTEX PHARMACEUTICALS INCORPORATED | Health Technology |
| Aziende private | 2 |
|---|---|
Critical Biologics Corp.
Critical Biologics Corp. Medical SpecialtiesHealth Technology Critical Biologics Corp. develops and commercializes diagnostics and therapeutics drugs. The firm focuses in the development of a theranostic platform to screen and treat both acute and chronic patients with low plasma gelsolin levels (hypogelsolinemia) at high risk of life-threatening complications. The company was founded by James W. Fordyce, Terence S. Russell, Shun Lee Po, and Thomas P. Stossel in 2006 and is headquartered in Cambridge, MA. | Health Technology |
Proteostasis Therapeutics, Inc.
 Proteostasis Therapeutics, Inc. BiotechnologyHealth Technology Proteostasis Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It engages in the discovery and development of novel therapeutics to treat cystic fibrosis (CF) and other diseases caused by an imbalance in the proteostasis network. The company was founded by William Balch, Jeffery W. Kelly, Andrew Dillin, Richard I. Morimoto, Alfred Lewis Goldberg, Daniel Finley, Christopher T. Walsh, and Randall W. King in 2006 and is headquartered in Boston, MA. | Health Technology |
- Borsa valori
- Insiders
- Po-Shun Lee
- Esperienza
